Nel (Sell, TP: NOK2.50) - Continues to underperform
Reported Q3 EBITDA of NOK-90m was far below consensus (NOK-61m) and our estimate (NOK-69m). The backlog keeps declining, and cash burn continues to exceed our expectations. Still, management remains hopeful, guiding for significantly improved EBITDA in Q4 and sees signs of a market recovery. Nel plans to increase focus on costs and expects 50% lower capex YOY. We had expected even lower 2025 capex, as capacity expansion projects in Norway and the US are completed, and we have thus increased our 2025e capex, resulting in higher cash burn. We reiterate our SELL and have lowered our target price to NOK2.5 (3).NEL ASA develops diagnostic tests for early detection of diseases. Co.'s patented method is based on identifying disease-specific gene expression signatures from sample materials, such as blood. Co.'s products in development phase include MCItect, for patients with Mild Cognitive Impairment (MCI) aimed to detect Alzheimer disease within two years prior to onset of dementia, and ADtect, for the detection of mild to moderate Alzheimer disease, as well as one project in discovery phase, namely AMYtect, for brain amyloid detection.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.